Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carasent AB (publ)APXZF 79 Cash Ratio is 0.33 as of Jun. 2026, which is 90% below its 10-year median of 3.31. GuruFocus rates APXZF with a GF Score™ of 79/100 and a GF Value™ of $0.18. The stock has 3 warning signs investors should review. Among 663 Healthcare Providers & Services companies, Carasent AB (publ) ranks worse than 66.37% on this metric.
Carasent AB (publ) has a Cash Ratio of 0.33. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Carasent AB (publ)'s Cash Ratio or its related term are showing as below:
APXZF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.32 Med: 3.31 Max: 121.08
Current: 0.33
During the past 13 years, Carasent AB (publ)'s highest Cash Ratio was 121.08. The lowest was 0.32. And the median was 3.31.
APXZF's Cash Ratio is ranked worse than 66.37% of 663
companies
in the Healthcare Providers & Services industry
Industry Median: 0.58
vs APXZF: 0.33
Carasent AB (publ) (OTCPK:APXZF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Carasent AB (publ) Cash Ratio Related Terms
Carasent AB (publ) Cash Ratio Historical Data
* Premium members only.
The historical data trend for Carasent AB (publ)'s Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Carasent AB (publ)'s Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carasent AB (publ) Cash Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s Cash Ratio distribution charts can be found below:
* The bar in red indicates where Carasent AB (publ)'s Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carasent AB (publ) (APXZF) has a Cash Ratio of 0.33 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Carasent AB (publ) and its competitors. This is 90% below median its historical median of 3.31. Over the past decade, Carasent AB (publ)'s Cash Ratio has ranged from 0.32 to 121.08. According to the industry distribution chart, Carasent AB (publ) ranks #440 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 66.4%.
Is Carasent AB (publ)'s Cash Ratio too high?
Carasent AB (publ)'s current Cash Ratio of 0.33 is 90% below median its 10-year median of 3.31. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 121.08. The Healthcare Providers & Services industry median Cash Ratio is 0.58. Carasent AB (publ)'s value of 0.33 is 43.1% below this industry median. Based on the distribution chart, Carasent AB (publ) ranks #440 out of 663 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Carasent AB (publ) has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s Cash Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #440 out of 663 companies for Cash Ratio. This places Carasent AB (publ) in the lower half of its industry. The industry median Cash Ratio is 0.58. Carasent AB (publ)'s value of 0.33 is 43.1% below this benchmark. Historically, Carasent AB (publ)'s own Cash Ratio has ranged from 0.32 to 121.08 over the past decade. While the company's 10-year median is 3.31 vs. the industry median of 0.58, Carasent AB (publ) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Healthcare Providers & Services company?
The median Cash Ratio among Healthcare Providers & Services companies is 0.58, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carasent AB (publ)'s current Cash Ratio of 0.33 is 43.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Carasent AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median Cash Ratio is 0.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current Cash Ratio is 0.33, which is 90% below median its own 10-year median of 3.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (APXZF) has a current Cash Ratio of 0.33. The stock's GF Value™ is $0.18, compared to a current price of $0.15 — trading 16.7% below its estimated fair value. The current Cash Ratio is 0.33, which is 90% below median its 10-year median of 3.31 and 43.1% below the Healthcare Providers & Services industry median of 0.58. Carasent AB (publ)'s overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Carasent AB (publ) (APXZF), the current Cash Ratio is 0.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (APXZF) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of $0.15 is trading 16.7% below its estimated GF Value™ of $0.18.
Key valuation signals for APXZF:
Cash Ratio: 0.33 (90% below median its 10-year median of 3.31)
GF Value™: $0.18 vs. price of $0.15 (16.7% below fair value)
Industry Position: 43.1% below the Healthcare Providers & Services median (#440 of 663)
No single metric tells the full story. See the APXZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
79GF Score
Get the complete analysis for APXZF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APXZF has been successfully added to your 
